Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice
- PMID: 29938577
- PMCID: PMC6086295
- DOI: 10.1080/21505594.2018.1489198
Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice
Abstract
Background: Cystic fibrosis (CF) lung infection is a complex condition where opportunistic pathogens and defective immune system cooperate in developing a constant cycle of infection and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of virulence factors involved in host immune response and lung tissue damage. In this study, we examined the possible anti-inflammatory effects of molecules inhibiting P. aeruginosa virulence factors.
Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial culture supernatant from different P. aeruginosa strains. Inhibition of virulence factors by sub-inhibitory concentrations of clarithromycin and by protease inhibitors was evaluated. Lung inflammatory response was monitored by in vivo bioluminescence imaging in wild-type and CFTR-knockout mice expressing a luciferase gene under the control of a bovine IL-8 promoter.
Results: The amount of proteases, pyocyanin and pyoverdine secreted by P. aeruginosa strains was reduced after growth in the presence of a sub-inhibitory dose of clarithromycin. Intratracheal challenge with culture supernatant containing bacteria-released products induced a strong IL-8-mediated response in mouse lungs while lack of virulence factors corresponded to a reduction in bioluminescence emission. Particularly, sole inactivation of proteases by inhibitors Ilomastat and Marimastat also resulted in decreased lung inflammation.
Conclusions: Our data support the assumption that virulence factors are involved in P. aeruginosa pro-inflammatory action in CF lungs; particularly, proteases seem to play an important role. Inhibition of virulence factors production and activity resulted in decreased lung inflammation; thus, clarithromycin and protease inhibitors potentially represent additional therapeutic therapies for P. aeruginosa-infected patients.
Keywords: Cystic fibrosis; Pseudomonas aeruginosa; clarithromycin; in vivo imaging; lung inflammation; protease inhibitors; virulence factors.
Figures





Similar articles
-
Protease inhibitors elicit anti-inflammatory effects in CF mice with Pseudomonas aeruginosa acute lung infection.Clin Exp Immunol. 2021 Jan;203(1):87-95. doi: 10.1111/cei.13518. Epub 2020 Oct 12. Clin Exp Immunol. 2021. PMID: 32946591 Free PMC article.
-
In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin.J Transl Med. 2015 Aug 4;13:251. doi: 10.1186/s12967-015-0615-9. J Transl Med. 2015. PMID: 26239109 Free PMC article.
-
Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo.Cell Physiol Biochem. 2017;42(4):1657-1669. doi: 10.1159/000479411. Epub 2017 Jul 24. Cell Physiol Biochem. 2017. PMID: 28738346
-
Role of quorum sensing by Pseudomonas aeruginosa in microbial keratitis and cystic fibrosis.Microbiology (Reading). 2008 Aug;154(Pt 8):2184-2194. doi: 10.1099/mic.0.2008/019281-0. Microbiology (Reading). 2008. PMID: 18667552 Review.
-
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28713772 Free PMC article. Review.
Cited by
-
Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.Cells. 2020 Aug 24;9(9):1952. doi: 10.3390/cells9091952. Cells. 2020. PMID: 32847034 Free PMC article. Review.
-
Antibiofilm activity of Prevotella species from the cystic fibrosis lung microbiota against Pseudomonas aeruginosa.Biofilm. 2024 Jun 8;7:100206. doi: 10.1016/j.bioflm.2024.100206. eCollection 2024 Jun. Biofilm. 2024. PMID: 38975276 Free PMC article.
-
Hypermutation as an Evolutionary Mechanism for Achromobacter xylosoxidans in Cystic Fibrosis Lung Infection.Pathogens. 2020 Jan 21;9(2):72. doi: 10.3390/pathogens9020072. Pathogens. 2020. PMID: 31973169 Free PMC article.
-
The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against Pseudomonas aeruginosa.Pharmaceutics. 2021 Apr 18;13(4):577. doi: 10.3390/pharmaceutics13040577. Pharmaceutics. 2021. PMID: 33919624 Free PMC article.
-
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics.Cells. 2023 Jan 3;12(1):199. doi: 10.3390/cells12010199. Cells. 2023. PMID: 36611992 Free PMC article. Review.
References
-
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001. - PubMed
-
- Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 2013;19(3):251–258. - PubMed
-
- Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol. 2010;300(8):557–562. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical